Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo

Human Psychopharmacology

Volumn 26, Issue 1, 2011, Pages 72-76

  Schutters, Sara I J ^a,b   Van Megen, Harold J G M ^a,c   Van Veen, J Frederieke ^a,d   Schruers, Koen R J ^b   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Meerkanten GGZ   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antidepressants; Mirtazapine; Paroxetine; Social anxiety disorder

Indexed keywords

MIRTAZAPINE; PAROXETINE; PLACEBO;

ADULT; ARIZONA SEXUAL EXPERIENCES SCALE; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; GENERALIZED ANXIETY DISORDER; GENERALIZED SOCIAL ANXIETY DISORDER; HUMAN; LIEBOWITZ SOCIAL ANXIETY SCALE; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOCIAL PHOBIA; WEIGHT GAIN;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANXIETY DISORDERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 79953244446     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1165     Document Type: Article

References (27)

1. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. 1999. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 175: 120-126. (Pubitemid 29359373)
2. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. 2006. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21: 159-169. (Pubitemid 43740307)
3. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. 2006. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67: 1428-1434.
4. Besson A, Haddjeri N, Blier P, de Montigny C. 2000. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol 10: 177-188. (Pubitemid 30227618)
5. Carpenter LL, Yasmin S, Price LH. 2002. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 15: 183-188. (Pubitemid 34127908)
6. de Boer T. 1995. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 10: 19S-23S.
7. Gelenberg AJ, McGahuey C, Laukes C, et al. 2000. Mirtazapine substitution in SSRI-induced sexual dysfunction. J Clin Psychiatry 61: 356-360. (Pubitemid 30345937)
8. Gillman PK. 2006. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol 21: 117-125.
9. Haberfellner EM. 2007. A review of the assessment of antidepressant- induced sexual dysfunction used in randomized, controlled clinical trials. Pharmacopsychiatry 40: 173-182. (Pubitemid 47535743)
10. Hamilton M. 1960. A rating scale for depression. Neurol Neurosurg Psychiatry 23: 56-62.
11. Liebowitz MR. 1987. Social phobia. Mod Probl Pharmacopsychiatry 22: 141-173.
12. Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. 2002. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 63: 66-74. (Pubitemid 34113490)
13. McGahuey CA, Gelenberg AJ, Laukes CA, et al. 2000. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Therapy 26: 25-40. (Pubitemid 30046590)
14. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. 2001. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 62 (Suppl 3): 10-21. (Pubitemid 32164676)
15. Montgomery SA, Lecrubier Y, Baldwin DS, et al. 2004. ECNP Consensus Meeting, March 2003.Guidelines for the investigation of efficacy in social anxiety disorder. Eur Neuropsychopharmacol 14: 425-433.
16. Muehlbacher M, Nickel MK, Nickel C, et al. 2005. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. . J Clin Psychopharmacol 25: 580-583. (Pubitemid 41669054)
17. Nutt DJ. 2002. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol 17(Suppl 1): 37-41.
18. Ozmenler NK, Karlidere T, Bozkurt A, et al. 2008. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 23: 321-326. (Pubitemid 351982669)
19. Pallanti S, Quercioli L, Bruscoli M. 2004. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 65: 1394-1399.
20. Schutters SIJ, van Megen HJGM, Van Veen JF, Denys DAJP, Westenberg HGM. 2010. Mirtazapine in generalised social anxiety disorder: a randomised, double-blind, placebo-controlled study. Int Clin Psychopharmacol 25: 302-304.
21. Serretti A, Chiesa A. 2009. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 29: 259-266.
22. Sheehan DV, Lecrubier Y, Sheehan KH, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33. (Pubitemid 29001829)
23. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. 1998. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280: 708-713. (Pubitemid 28405295)
24. Stein DJ, Baldwin DS, Bandelow B, et al. 2010. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Curr Psychiatry Rep 12: 471-477.
25. Van Ameringen M, Mancini C, Pipe B, Bennett M. 2004. Optimizing treatment in social phobia: a review of treatment resistance. CNS Spectr 9: 753-762. (Pubitemid 39473445)
26. Van den Heuvel MW, Kleijn HJ, Peeters PAM. 2001. Bioequivalence trial of orally disintegrating mirtazapine tablets and conventional oral mirtazapine tablets in healthy volunteers. Clin Drug Invest 21: 437-442. (Pubitemid 32553607)
27. Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. 2010. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol 24: 489-496.